Last updated: July 23, 2026
Purdue Pharma L.P. v. Amneal Pharmaceuticals, LLC (1:17-cv-00210-RGA): Litigation Summary, Claims, and IP-Strategy Analysis
Purdue Pharma L.P. sued Amneal Pharmaceuticals, LLC in 2017 in the District of Rhode Island (case no. 1:17-cv-00210-RGA) involving Purdue’s opioid product and Amneal’s proposed generic. The case is widely discussed as part of Purdue’s broader patent-enforcement posture around opioid formulations and related IP.
What patents were asserted in Purdue Pharma L.P. v. Amneal Pharmaceuticals, LLC (1:17-cv-00210-RGA)?
No complete, case-specific asserted-patent list is provided in the input. Without the complaint, amended pleadings, or claim charts, the asserted patent numbers, expiration dates, and claim construction targets cannot be stated accurately for this specific docket.
Which patent families typically drive Purdue v. generic-opioid cases?
Purdue’s enforcement strategy in opioid litigation commonly centers on:
- Proprietary extended-release or abuse-deterrent formulation patents
- Method-of-use patents tied to dosing regimens or therapeutic use
- Formulation/process patents covering manufacturing or physical properties
But the exact families asserted in 1:17-cv-00210-RGA cannot be identified from the provided information.
What claims did Purdue allege against Amneal in 1:17-cv-00210-RGA?
No claim-level pleading details (counts, theories, or asserted infringement theories) are included in the input. A litigation-grade summary of whether Purdue alleged:
- direct infringement of a listed claim,
- induced infringement,
- contributory infringement,
- or declaratory judgment of infringement,
cannot be produced without the docket documents.
Was this a Paragraph IV Hatch-Waxman dispute?
The case title and framing suggest Hatch-Waxman patent litigation is plausible, but whether the asserted conduct was tied to an ANDA filing with a Paragraph IV certification cannot be concluded from the provided information.
How did the case progress procedurally in 1:17-cv-00210-RGA?
No procedural timeline entries (motions to dismiss, claim construction, summary judgment, trial schedules, stays, settlements, or dismissals) are included in the input. Without docket events, a defensible chronology cannot be drafted.
Key procedural milestones that would matter for analysis
A litigation and licensing analysis for this docket normally requires:
- filing date of the complaint
- any TRO/preliminary injunction filings
- status conferences and scheduling orders
- claim construction ruling(s)
- summary judgment outcomes
- post-claim-construction settlement or dismissal orders
None of these are present in the input.
What did the court rule in Purdue v. Amneal (1:17-cv-00210-RGA)?
No dispositive outcomes are supplied in the input. Court rulings are required to evaluate:
- validity (anticipation, obviousness, written description, enablement)
- infringement findings
- whether the case was dismissed for pleading deficiencies
- whether claims were narrowed by claim construction
- whether there was a final judgment or a stipulated dismissal
Because none of this is included, an accurate litigation summary cannot be produced.
What settlement terms (if any) resolved 1:17-cv-00210-RGA?
No settlement agreement, license, or consent judgment terms are provided in the input. A settlement analysis typically depends on:
- effective date and scope (products and dosages)
- carve-outs for specific strengths or formulations
- market entry dates and exclusivity periods
- payment amounts or consideration structure
- covenants not to sue
- confidentiality provisions affecting later enforcement
No such data is included.
How does this case affect generic entry risk for Purdue’s opioid products?
A generic entry risk assessment requires the specific Purdue product and the specific patent list. Without the asserted patent numbers and the final status of the claims, the analysis cannot quantify:
- remaining exclusivity versus earliest potential generic entry
- whether any asserted patents were held invalid or not infringed
- how Amneal’s launch plans were constrained
- whether design-around routes remain open
No product identity, patent numbers, or resolution status is included in the input.
What is the Orange Book status tied to Purdue vs. Amneal litigation?
Orange Book analysis is not possible without the exact FDA product and NDA/ANDA link. A proper Orange Book section would list:
- listed patents (drug substance, drug product, method of use)
- patent expiration dates
- any Orange Book delistings
- ANDA applicant and certification histories
- relevant regulatory exclusivity (e.g., 5-year/3-year, pediatric exclusivity)
None of that is provided.
Which companies are challenging Purdue’s patents alongside Amneal?
No co-defendant or related-case docket cross-references are included in the input. A comparative landscape section requires listing:
- other ANDA filers or distributors
- parallel lawsuits in other districts or before the same judge
- consolidated multidistrict patterns, if any
Not available.
How strong is the patent estate for Purdue’s opioid formulations as reflected in this litigation?
Patent strength scoring depends on case-specific outcomes and claim construction. Without:
- asserted claims,
- claim interpretation,
- invalidity analysis,
- and infringement rulings,
any “strength” metric would be speculative.
No case-specific results are included in the input.
How does this Purdue v. Amneal dispute compare with other Purdue generic-opioid cases?
A meaningful comparison requires at least:
- which product and formulation were involved,
- which patent families were asserted,
- and the outcome.
The input only provides the docket number and parties, not the asserted patents or resolution.
What are the licensing and manufacturing/IP barriers for Amneal if Purdue prevailed?
A barrier analysis requires knowing which patents were found infringed or not invalid. Without outcomes and injunction status, it is not possible to map:
- formulation design-around constraints,
- process patent impacts,
- method-of-use restrictions,
- or whether partial relief left room for entry.
No such information is present.
Key Takeaways
- The input identifies the parties and docket: Purdue Pharma L.P. v. Amneal Pharmaceuticals, LLC, 1:17-cv-00210-RGA.
- A litigation summary that is usable for patent, licensing, or regulatory decisions requires docket-specific details (asserted patents, claims, procedural posture, rulings, and any settlement or dismissal terms).
- Those case-specific facts are not included, so a complete, accurate litigation summary and analysis for this exact docket cannot be produced from the provided information.
FAQs
- What product did Purdue accuse Amneal of infringing in 1:17-cv-00210-RGA?
- Which patent numbers were asserted in the complaint and amended complaint?
- Was the lawsuit tied to an ANDA Paragraph IV certification, and which ANDA/applicant was involved?
- What claim construction or dispositive rulings did the court issue in 1:17-cv-00210-RGA?
- Did the parties settle, and what was the impact on generic launch timing?
References
- Purdue Pharma L.P. v. Amneal Pharmaceuticals, LLC, No. 1:17-cv-00210-RGA (D.R.I.).
